Marshall Wace LLP Increases Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Marshall Wace LLP lifted its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 332.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 264,523 shares of the company's stock after buying an additional 203,361 shares during the quarter. Marshall Wace LLP owned about 0.63% of SI-BONE worth $3,709,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of SI-BONE in the fourth quarter worth about $171,000. Barclays PLC raised its stake in SI-BONE by 2.7% during the 4th quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares during the period. Sterling Capital Management LLC raised its stake in SI-BONE by 12.9% during the 4th quarter. Sterling Capital Management LLC now owns 120,795 shares of the company's stock valued at $1,694,000 after purchasing an additional 13,828 shares during the period. Raymond James Financial Inc. bought a new stake in SI-BONE during the 4th quarter valued at approximately $1,233,000. Finally, Renaissance Technologies LLC bought a new stake in SI-BONE during the 4th quarter valued at approximately $1,562,000. Institutional investors own 98.11% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on SIBN shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Truist Financial reaffirmed a "buy" rating and issued a $22.00 price objective (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC lifted their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $24.40.

SI-BONE Trading Down 3.5 %

SIBN traded down $0.50 during trading hours on Wednesday, reaching $13.78. 110,592 shares of the company's stock traded hands, compared to its average volume of 359,210. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.16. The firm has a market capitalization of $585.00 million, a PE ratio of -14.98 and a beta of 1.02. The firm has a 50-day moving average price of $14.85 and a 200 day moving average price of $14.66. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. As a group, sell-side analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares of the company's stock, valued at $3,462,574.92. This represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,776 shares of company stock worth $96,644 in the last three months. Company insiders own 3.90% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.